Telomere Biology Disorders: Molecular Mechanisms and Clinical Impact

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Telomere biology disorders (TBDs) are inherited conditions characterized by mutations in genes essential for telomere maintenance, leading to critically short telomeres (<1st percentile for age) and premature cellular senescence, primarily affecting high-turnover tissues like bone marrow, lungs, and liver.
• The molecular basis involves defects in the telomerase enzyme complex (TERT, TERC, DKC1) or shelterin proteins (TINF2, POT1, ACD), resulting in progressive telomere attrition due to the end-replication problem and oxidative damage.
• Clinical manifestations span a spectrum from childhood dyskeratosis congenita (DC) with mucocutaneous abnormalities and bone marrow failure to adult-onset pulmonary fibrosis and aplastic anemia, with significant variable expressivity and incomplete penetrance influenced by genetic modifiers and environmental factors.
• Diagnosis relies on demonstrating abnormally short telomeres, typically via flow-FISH on leukocyte subsets, coupled with genetic testing to identify causative mutations in at least 14 known TBD genes, including TERT and TERC as common autosomal dominant causes.
• Management is supportive, with androgen therapy (danazol) for bone marrow failure, antifibrotic agents for pulmonary fibrosis, and hematopoietic stem cell transplantation (HSCT) as a potentially curative but high-risk option for severe bone marrow failure.
• The pathogenesis involves telomere uncapping, activating ATM/ATR and p53 pathways, leading to stem cell exhaustion, senescence, and genomic instability, contributing to organ failure and increased cancer risk.

Introduction to Telomere Biology Disorders

What Are Telomere Biology Disorders?

Telomere biology disorders (TBDs) are a group of inherited conditions caused by mutations in genes required for telomere maintenance, resulting in critically short telomeres that trigger premature cellular senescence and organ failure. The unifying molecular feature is defective telomere homeostasis, leading to telomere lengths below the first percentile for age. These disorders span a clinical continuum from severe childhood-onset dyskeratosis congenita (DC) to adult-onset idiopathic pulmonary fibrosis and aplastic anemia, with considerable phenotypic variability even within families carrying the same mutation.

The genetic basis of TBDs lies in mutations affecting either the telomerase enzyme complex (which elongates telomeres) or proteins that protect and process telomeric DNA. Because telomerase activity is limiting in human somatic cells, even heterozygous loss-of-function mutations can reduce telomere maintenance below the threshold required for long-term tissue renewal. The tissues most affected—bone marrow, lungs, and liver—are those with high cellular turnover and continuous regenerative demand.

Historical Context and Naming

Dyskeratosis congenita was first described in 1906 by Zinsser as a syndrome characterized by the triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. For decades, the condition remained poorly understood, with bone marrow failure recognized as the leading cause of death. The molecular basis remained obscure until 1998, when mutations in DKC1, encoding dyskerin, were identified in X-linked DC. This discovery linked DC to telomere biology, as dyskerin is a core component of telomerase.

The term "telomere biology disorder" emerged in the 2000s as genetic testing revealed that mutations in telomerase genes (TERT, TERC) could cause adult-onset pulmonary fibrosis and aplastic anemia without the classic mucocutaneous features of DC. This expanded the phenotype from a rare pediatric syndrome to a spectrum of age-related diseases. The recognition that up to 15% of familial pulmonary fibrosis and 5% of acquired aplastic anemia cases carry telomere gene mutations has transformed clinical practice, making telomere length measurement a routine diagnostic tool in hematology and pulmonology.

Telomere Structure and Function

Telomeric DNA and Shelterin Proteins

Telomeres are specialized nucleoprotein structures at the ends of linear chromosomes. Human telomeric DNA consists of tandem repeats of the hexanucleotide sequence TTAGGG, extending 5–15 kilobases (kb) in length at birth. The G-rich strand runs 5′→3′ toward the chromosome end, terminating in a single-stranded 3′ overhang of 50–300 nucleotides. This overhang is essential for telomere function and is generated during replication by the action of the exonuclease Apollo and the helicase RTEL1.

The telomeric DNA is bound by the shelterin complex, a six-protein assembly that protects chromosome ends from being recognized as double-strand breaks. Shelterin comprises TRF1 and TRF2 (which bind double-stranded TTAGGG repeats), POT1 (which binds the single-stranded overhang), and the bridging proteins TIN2, TPP1, and RAP1. TRF2 is critical for the formation and stabilization of the T-loop, a lasso-like structure in which the single-stranded overhang invades the proximal double-stranded telomeric DNA, sequestering the chromosome end.

The Telomere Definition extends beyond simple DNA sequence: the telomere is a dynamic structure whose length and integrity are maintained by the coordinated action of telomerase, shelterin, and DNA replication machinery. Shelterin proteins also regulate telomerase access to the telomere, with TPP1–POT1 forming a recruitment platform that binds the telomerase subunit TERT. This ensures that telomerase acts processively at chromosome ends rather than at internal DNA breaks.

Telomere Shortening and the Hayflick Limit

Human somatic cells lack sufficient telomerase activity to maintain telomere length indefinitely. During each round of DNA replication, the end-replication problem—the inability of DNA polymerase to synthesize the extreme 3′ end of the lagging strand—results in the loss of 50–200 base pairs of telomeric DNA per cell division. This progressive erosion is compounded by oxidative damage, which introduces single-strand breaks in telomeric DNA that are repaired inefficiently.

When telomeres shorten to a critical threshold, typically 4–5 kb, they lose the ability to bind shelterin effectively. The resulting Telomere Shortening triggers a DNA damage response at chromosome ends, activating the ATM/ATR kinase pathways. This leads to one of three outcomes: cellular senescence (irreversible growth arrest), apoptosis, or genomic instability. The Hayflick limit, first described by Leonard Hayflick in 1961, is the finite number of cell divisions (approximately 50–70 for human fibroblasts) that cells can undergo before reaching this senescence checkpoint.

The rate of telomere shortening is not uniform across tissues. Highly proliferative tissues such as bone marrow hematopoietic stem cells, intestinal epithelium, and skin show the most rapid attrition. This explains why these tissues are the primary targets of dysfunction in TBDs. The relationship between telomere length and aging is explored further in Telomere Aging, which describes how telomere erosion contributes to organismal aging and age-related disease.

Telomerase and Telomere Maintenance

Telomerase Components and Biogenesis

Telomerase is a ribonucleoprotein enzyme that adds TTAGGG repeats to chromosome ends. The core enzyme consists of two essential components: telomerase reverse transcriptase (TERT), a catalytic protein of 1132 amino acids, and telomerase RNA component (TERC), a 451-nucleotide RNA that provides the template for telomere synthesis. The template region of TERC is complementary to the telomeric repeat, containing the sequence 3′-CAAUCCCAAUC-5′, which directs the addition of TTAGGG repeats.

The assembly of active telomerase requires additional proteins. Dyskerin, encoded by DKC1, binds a specific hairpin structure in TERC called the H/ACA box and is required for TERC stability and accumulation. Without dyskerin, TERC is rapidly degraded, and telomerase activity is lost. Other accessory factors include NOP10, NHP2, and GAR1, which form the H/ACA ribonucleoprotein complex, and TCAB1, which directs telomerase to Cajal bodies where it is stored and recruited to telomeres during S phase.

The biogenesis of telomerase is tightly regulated. TERC is transcribed by RNA polymerase II and processed to its mature form, while TERT is translated in the cytoplasm and imported into the nucleus. The mature telomerase complex is assembled in Cajal bodies, where it colocalizes with coilin and TCAB1. Telomerase activity is restricted to specific cell types: embryonic stem cells, adult stem cells, germ cells, and activated lymphocytes. Most somatic cells express TERT at undetectable levels, although TERC is present in many tissues.

Regulation of Telomerase Activity

Telomerase activity is regulated at multiple levels: transcriptional control of TERT, alternative splicing of TERT mRNA, post-translational modification, and subcellular localization. The TERT promoter contains binding sites for multiple transcription factors, including c-Myc, Sp1, and the estrogen receptor, which activate transcription. Conversely, the tumor suppressor p53 and the retinoblastoma protein indirectly repress TERT expression by inhibiting c-Myc activity.

The Telomere Replication process requires the coordinated action of telomerase with the conventional DNA replication machinery. During S phase, the replisome replicates the bulk of telomeric DNA, while telomerase extends the newly synthesized leading strand. The CST complex (CTC1, STN1, TEN1) terminates telomerase action and coordinates with DNA polymerase α to fill in the complementary strand. Mutations in CTC1 cause Coats plus syndrome, a TBD with prominent neurological and vascular features.

In cells that lack telomerase, a minority of cancers and immortalized cell lines maintain telomeres through the alternative lengthening of telomeres (ALT) pathway. ALT relies on homologous recombination between telomeric sequences, using the existing telomeric DNA as a template for synthesis. ALT cells are characterized by the presence of ALT-associated promyelocytic leukemia bodies (APBs), which contain telomeric DNA, recombination proteins, and PML. While ALT is rare in TBDs, understanding this pathway is important because some TBD patients with telomerase mutations may develop tumors that activate ALT.

Genetic Causes of Telomere Biology Disorders

Autosomal Dominant, Recessive, and X-Linked Inheritance

TBDs are genetically heterogeneous, with mutations in at least 14 genes identified to date. The inheritance patterns reflect the fundamental biology of telomere maintenance: because telomerase is a multimeric complex and haploinsufficiency is sufficient to cause disease, autosomal dominant inheritance is common. However, autosomal recessive and X-linked forms also occur.

Mutations in TERT and TERC are the most common causes of autosomal dominant TBDs, accounting for approximately 10% of familial pulmonary fibrosis and 5% of aplastic anemia cases. These mutations typically reduce telomerase activity by 50% or more, leading to progressive telomere shortening across generations—a phenomenon called genetic anticipation. Each generation inherits shorter telomeres, resulting in earlier disease onset and increased severity in successive generations.

Penetrance and Variable Expressivity

A striking feature of TBDs is variable expressivity and incomplete penetrance. Within a single family carrying the same TERT mutation, some members may develop pulmonary fibrosis at age 60, others may have aplastic anemia at age 30, and still others may remain asymptomatic throughout life. This variability reflects the influence of genetic modifiers, environmental factors (particularly smoking and occupational exposures), and stochastic telomere shortening.

The concept of "telomere length as a quantitative trait" is central to understanding this variability. Telomere length at birth is determined by the starting length inherited from parents and the efficiency of telomere maintenance during early development. Individuals with telomerase mutations begin life with shorter telomeres, but the rate of attrition is influenced by oxidative stress, inflammation, and proliferative demand. This explains why two siblings with the same mutation can have discordant phenotypes.

Clinical Manifestations and Disease Spectrum

Classic Dyskeratosis Congenita

Classic DC presents in childhood with the diagnostic triad of reticulated skin hyperpigmentation (present in ~90% of patients), nail dystrophy (~85%), and oral leukoplakia (~80%). The skin pigmentation typically appears first, often on the neck, chest, and upper arms, with a lace-like or reticulated pattern. Nail changes range from longitudinal ridging to complete nail loss. Oral leukoplakia affects the buccal mucosa, tongue, and palate and carries a risk of malignant transformation.

Bone marrow failure develops in approximately 80% of DC patients by age 30 and is the leading cause of death. The onset is insidious, with thrombocytopenia often preceding anemia and neutropenia. The bone marrow becomes progressively hypocellular, reflecting the exhaustion of hematopoietic stem cells. Patients also have an elevated risk of myelodysplastic syndrome and acute myeloid leukemia.

Other features include pulmonary fibrosis (20% of patients), liver disease (including cirrhosis and hepatocellular carcinoma), esophageal strictures, and developmental abnormalities such as microcephaly, growth retardation, and learning difficulties. The severe form of DC, Hoyeraal-Hreidarsson syndrome, presents in infancy with cerebellar hypoplasia, immunodeficiency, and intrauterine growth restriction.

Adult-Onset Presentations

The recognition that TBDs can present in adulthood has expanded the clinical spectrum considerably. Adult-onset pulmonary fibrosis is the most common presentation, with a median age of onset in the sixth decade. The radiological and histological pattern is usual interstitial pneumonia, indistinguishable from idiopathic pulmonary fibrosis. However, patients with TBDs tend to have more rapid disease progression and poorer survival compared to those without telomere mutations.

Aplastic anemia in adults can also be the presenting feature of a TBD. These patients typically have severe pancytopenia and a hypocellular bone marrow. The distinction from acquired aplastic anemia is clinically important because TBD patients have increased sensitivity to immunosuppressive therapy and higher rates of treatment-related toxicity. Additionally, they are at risk for developing other TBD manifestations, such as pulmonary fibrosis, after hematopoietic stem cell transplantation.

Liver disease, including cryptogenic cirrhosis and nodular regenerative hyperplasia, is increasingly recognized as a manifestation of TBDs. The liver disease may precede or follow the hematological and pulmonary manifestations. Some patients present with isolated liver disease and are found to have telomere mutations only after extensive evaluation.

The term "short telomere syndrome" is used to describe patients with telomere length below the first percentile who present with any combination of these features. The Telomere Health concept encompasses not only the absence of disease but also the maintenance of telomere length within a functional range across the lifespan.

Molecular Mechanisms of Disease Pathogenesis

Telomere Uncapping and DNA Damage Signaling

The pathogenesis of TBDs begins when telomeres become critically short, typically below 4 kb. At this length, the telomere can no longer bind sufficient shelterin to maintain the protective T-loop structure. The exposed chromosome end resembles a double-strand break and is recognized by the MRN complex (MRE11-RAD50-NBS1), which activates ATM kinase. Concurrently, the single-stranded overhang is bound by RPA, activating ATR kinase through the ATRIP interaction.

The activation of ATM and ATR leads to phosphorylation of downstream effectors, including CHK2 and CHK1, which in turn activate p53. The p53 pathway then induces cell cycle arrest through p21 (CDKN1A) and promotes senescence or apoptosis depending on cellular context. In tissues with high turnover, such as the bone marrow, this results in depletion of the stem cell pool. The Telomere Chromosome instability that results from uncapped telomeres also promotes chromosomal fusions and breakage-fusion-bridge cycles, contributing to cancer predisposition.

The DNA damage response at telomeres is not an all-or-nothing phenomenon. Individual telomeres within a cell may be at different lengths, and the shortest telomere determines the cellular response. This "shortest telomere" model explains why cells can have an average telomere length in the normal range yet still undergo senescence—it is the critically short telomere that triggers the checkpoint.

Impact on Stem Cell Function

Stem cells are particularly vulnerable to telomere dysfunction because they must self-renew throughout the lifespan. Hematopoietic stem cells (HSCs) express low levels of telomerase, sufficient to slow but not prevent telomere attrition. In TBDs, the reduced telomerase activity accelerates this decline, leading to premature exhaustion of the HSC pool.

The mechanism of stem cell failure involves both cell-intrinsic and cell-extrinsic factors. Intrinsically, telomere shortening activates p53, inducing senescence and apoptosis in HSCs. This reduces the number of functional stem cells and impairs their ability to reconstitute the hematopoietic system. Extrinsically, the inflammatory microenvironment of the failing bone marrow produces cytokines such as tumor necrosis factor-α and transforming growth factor-β, which further suppress hematopoiesis.

Similar mechanisms operate in other affected tissues. In the lung, alveolar type II cells—the progenitor cells of the alveolar epithelium—undergo senescence when telomeres become critically short. This impairs the repair of alveolar injury, leading to progressive fibrosis. In the liver, hepatocyte senescence and impaired regeneration contribute to cirrhosis and nodular regenerative hyperplasia.

The systemic nature of telomere dysfunction is reflected in the multi-organ involvement seen in TBDs. The Telomere Length measurement provides a quantitative biomarker that correlates with disease severity and can predict the risk of complications.

Diagnostic Approaches and Laboratory Methods

Telomere Length Assays

The diagnosis of a TBD requires demonstration of abnormally short telomeres and, ideally, identification of a causative genetic mutation. Telomere length is most commonly measured by flow cytometry with fluorescent in situ hybridization (flow-FISH), which quantifies telomere length in individual leukocyte subsets. The assay uses a peptide nucleic acid probe complementary to the TTAGGG repeat, and the fluorescence intensity is proportional to telomere length.

Flow-FISH results are expressed as telomere length in kilobases or as a percentage of the age-adjusted normal range. Telomere length below the first percentile for age in more than one leukocyte subset is considered diagnostic of a TBD. The test is particularly useful in children, where the age-dependent decline in telomere length is steepest. In adults, the interpretation is more challenging because the normal range widens with age.

Southern blot analysis of terminal restriction fragments (TRF) is an alternative method that measures the mean length of telomeric restriction fragments. This method is more labor-intensive and requires more DNA but provides information about the distribution of telomere lengths. Quantitative PCR (qPCR) is a high-throughput method that measures telomere length relative to a single-copy gene (T/S ratio), but it has greater inter-assay variability and is less suitable for clinical diagnosis.

The Telomere Testing approach in clinical practice typically begins with flow-FISH on peripheral blood leukocytes. If telomere length is below the first percentile, genetic testing is performed to identify the causative mutation. However, a normal telomere length does not exclude a TBD, particularly in adults with pulmonary fibrosis who may have telomere lengths in the low-normal range.

Genetic Testing Panels

Genetic testing for TBDs uses targeted gene panels that include all known TBD genes. Next-generation sequencing allows simultaneous analysis of multiple genes at reasonable cost. The panels typically include TERT, TERC, DKC1, TINF2, RTEL1, PARN, CTC1, WRAP53, NOP10, NHP2, ACD, POT1, DCLRE1B, and ZCCHC8.

The interpretation of genetic variants requires careful consideration of the inheritance pattern, the predicted effect on protein function, and the allele frequency in the general population. Loss-of-function variants (nonsense, frameshift, splice site) are generally pathogenic, while missense variants require functional studies or segregation analysis. The presence of a pathogenic variant in a gene with a known TBD association, combined with short telomeres and compatible clinical features, confirms the diagnosis.

Genetic testing has implications beyond the individual patient. Because TBDs are inherited, family members may be at risk, and genetic counseling is essential. Prenatal testing and preimplantation genetic diagnosis are options for families with known mutations. However, the variable expressivity and incomplete penetrance make genetic counseling challenging, as the prediction of disease severity in an individual carrier is imprecise.

Current Treatments and Management Strategies

Medical Management

The management of TBDs is primarily supportive, focusing on the treatment of specific complications. Androgen therapy with danazol or oxymetholone is the mainstay of treatment for bone marrow failure in TBDs. Androgens stimulate telomerase activity in hematopoietic stem cells and increase telomere length in some patients. A clinical trial of danazol in patients with TBDs showed that 79% of patients had a hematological response, with significant increases in blood counts and stabilization of telomere length. However, androgens have significant side effects, including liver toxicity, fluid retention, and virilization, and require careful monitoring.

For patients with pulmonary fibrosis, antifibrotic agents such as pirfenidone and nintedanib are used, although their efficacy in TBD-associated fibrosis is less well established than in idiopathic pulmonary fibrosis. Oxygen therapy and pulmonary rehabilitation are important supportive measures. Patients with liver disease require monitoring for complications of cirrhosis, including variceal bleeding and hepatocellular carcinoma.

Transplantation and Gene Therapy Prospects

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for bone marrow failure in TBDs. However, the outcomes are worse than in other indications, with higher rates of graft failure, graft-versus-host disease, and regimen-related toxicity. The reduced-intensity conditioning regimens are preferred to minimize toxicity, but the underlying telomere dysfunction in recipient tissues, particularly the lungs and liver, increases the risk of complications. Pulmonary fibrosis and liver disease can be exacerbated by the conditioning regimen and by infections after transplantation.

Lung transplantation is an option for patients with end-stage pulmonary fibrosis. The outcomes are comparable to those in patients with idiopathic pulmonary fibrosis, but the systemic nature of the disease means that other organ involvement must be carefully evaluated before listing for transplantation. Liver transplantation has been performed in patients with TBD-associated cirrhosis, with acceptable outcomes.

Gene therapy approaches for TBDs are in preclinical development. The goal is to deliver a functional copy of the mutated gene to hematopoietic stem cells, restoring telomerase activity. For TERT mutations, this could involve lentiviral or retroviral delivery of the TERT cDNA. For TERC mutations, the small size of the RNA (451 nucleotides) makes it amenable to gene therapy vectors. However, concerns about the risk of insertional mutagenesis and the potential for increased cancer risk remain significant barriers to clinical translation.

Common Pitfalls and Study Tips for Students

Misconceptions to Avoid

Several common misconceptions can impede understanding of TBDs. The first is confusing telomerase with telomeres themselves. Telomeres are the DNA-protein structures at chromosome ends; telomerase is the enzyme that maintains them. Students should be precise: telomerase does not "protect" telomeres—shelterin does that—but rather elongates them.

A second misconception is that all short telomeres cause disease. Telomere length varies widely in the normal population, and many individuals with telomeres below the first percentile are healthy. The development of disease depends on the rate of telomere shortening, the proliferative demand of affected tissues, and the presence of additional genetic or environmental factors. Telomere length is a risk factor, not a deterministic cause.

A third misconception is that TBDs are the same as premature aging syndromes. While TBDs share features with progeroid syndromes such as Hutchinson-Gilford progeria, the underlying mechanisms differ. Progeria is caused by mutations in LMNA, encoding lamin A, which disrupts nuclear architecture, while TBDs result from defective telomere maintenance. The clinical features also differ: TBDs primarily affect highly proliferative tissues, while progeria affects connective tissues and the cardiovascular system.

Frequently Asked Questions

What is telomere biology disorder?

Telomere biology disorder (TBD) is an umbrella term for inherited conditions caused by mutations in genes required for telomere maintenance. These mutations lead to abnormally short telomeres, which trigger premature cellular senescence and organ failure. TBDs include dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, and adult-onset presentations such as pulmonary fibrosis and aplastic anemia.

How are telomere biology disorders inherited?

TBDs can be inherited in an autosomal dominant, autosomal recessive, or X-linked pattern, depending on the gene involved. Autosomal dominant inheritance is most common, particularly for TERT and TERC mutations. X-linked inheritance occurs with DKC1 mutations, affecting mostly males. Autosomal recessive inheritance is seen with mutations in RTEL1, CTC1, and other genes.

What are the symptoms of telomere biology disorders?

Symptoms vary by age of onset and affected organ systems. Classic dyskeratosis congenita presents in childhood with skin pigmentation, nail dystrophy, and oral leukoplakia, followed by bone marrow failure. Adult-onset TBDs typically present with pulmonary fibrosis, aplastic anemia, or liver disease. Other features include cancer predisposition, immunodeficiency, and developmental abnormalities.

How is telomere length measured?

Telomere length is most commonly measured by flow-FISH, which uses fluorescent probes to quantify telomere length in individual leukocytes. Southern blot analysis of terminal restriction fragments and quantitative PCR are alternative methods. Telomere length below the first percentile for age is considered diagnostic of a TBD.

Can telomere biology disorders be cured?

There is no cure for TBDs, but treatments can manage complications. Hematopoietic stem cell transplantation can cure bone marrow failure, and lung transplantation can treat end-stage pulmonary fibrosis. Androgen therapy can improve blood counts. Gene therapy approaches are in development but not yet clinically available.

What is the difference between telomerase and telomere?

A telomere is the protective DNA-protein structure at the ends of chromosomes, consisting of TTAGGG repeats bound by shelterin proteins. Telomerase is the enzyme that adds new telomeric repeats to chromosome ends. Telomerase contains a catalytic protein (TERT) and an RNA template (TERC). Telomeres protect chromosome ends; telomerase maintains telomere length.

Are telomere biology disorders the same as premature aging?

No. TBDs are distinct from classical premature aging syndromes such as Hutchinson-Gilford progeria. While TBDs cause premature dysfunction of highly proliferative tissues (bone marrow, lungs, liver), progeria affects connective tissues and the cardiovascular system. The molecular mechanisms also differ: TBDs result from defective telomere maintenance, while progeria is caused by mutations in nuclear envelope proteins.

Key Takeaways

• Telomere biology disorders are caused by mutations in genes required for telomere maintenance, leading to critically short telomeres and premature cellular senescence.
• Telomeres consist of TTAGGG repeats bound by the shelterin complex, which protects chromosome ends from DNA damage recognition.
• Telomerase, composed of TERT, TERC, and associated proteins including dyskerin, elongates telomeres in stem cells, germ cells, and activated lymphocytes.
• Major TBD genes include TERT, TERC, DKC1, TINF2, RTEL1, and PARN, with autosomal dominant, autosomal recessive, and X-linked inheritance patterns.
• Clinical presentations range from childhood dyskeratosis congenita with bone marrow failure to adult-onset pulmonary fibrosis and aplastic anemia.
• Critically short telomeres trigger the DNA damage response through ATM/ATR and p53, leading to stem cell exhaustion in affected tissues.
• Diagnosis requires telomere length measurement by flow-FISH and genetic testing; treatment includes androgen therapy, hematopoietic stem cell transplantation, and lung transplantation.
• Telomere length is a quantitative trait influenced by genetics, environment, and stochastic factors; short telomeres increase disease risk but do not guarantee disease development.

Further Reading

• Byrjalsen A et al. [Telomere biology disorders]. Ugeskrift for laeger. 2022. PubMed 35959813
• Calleri A, Simonetto DA. Telomere Disorders and the Liver. Clinics in liver disease. 2025. PubMed 40670029
• Rolles B et al. Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2024. PubMed 39371255
• Savage SA. Human telomeres and telomere biology disorders. Progress in molecular biology and translational science. 2014. PubMed 24993697
• Warsame F, Simonetto DA. Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations. Current hematologic malignancy reports. 2024. PubMed 38372947
• Patnaik MM, Kamath PS, Simonetto DA. Hepatic manifestations of telomere biology disorders. Journal of hepatology. 2018. PubMed 29758336

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks